Linkers serve as molecular bridges, connecting functional components like antibodies and payloads in antibody-drug conjugates (ADCs) to enable precise drug delivery. Their design dictates stability, release kinetics, and therapeutic efficacy, making them indispensable in ADC development and beyond.
Overview of Linkers
In the field of ADCs, linkers are specialized chemical or peptide-based structures that covalently bind two molecules (an antibody and cytotoxic drug in ADCs). Their primary function is to maintain conjugate stability during systemic circulation while enabling controlled payload release at the target site. This balance minimizes off-target toxicity and maximizes therapeutic index. Beyond ADCs, linkers are pivotal in prodrugs, molecular imaging probes, and protein degraders like PROTACs. Their versatility stems from tunable properties, including biodegradability, responsiveness to physiological triggers (e.g., pH, enzymes), and compatibility with diverse conjugation chemistries.
Fig.1 Various Linker payload designs for faster lysosomal cleavage and improved plasma stability. (Balamkundu & Liu, 2023)
Classification of Linkers
Linkers are categorized by their mechanism of payload release: cleavable and non-cleavable.
Cleavable Linkers
These are designed to break under specific biological conditions, inncluding:
- Protease-Sensitive Linkers: Incorporate peptide sequences (e.g., Val-Cit, Phe-Lys) cleaved by lysosomal proteases like cathepsin B. They are ideal for ADCs targeting internalizing antigens.
- Acid-Labile Linkers: Rely on low pH environments (e.g., endosomes) for hydrolysis. Examples include hydrazones, which offer rapid payload release but require careful stability optimization.
- Glutathione-Sensitive Linkers: Utilize disulfide bonds cleaved by intracellular glutathione, prevalent in tumor cells. These provide redox-dependent activation.
Non-Cleavable Linkers
These linkers remain intact during cellular processing, requiring full antibody degradation (e.g., lysosomal proteolysis) to release payloads. A prime example is the thioether linker in trastuzumab emtansine (T-DM1). Non-cleavable linkers enhance plasma stability but depend on target antigen internalization.
Roles of Linkers
Linkers in ADCs are not just connectors—they are central to ADC performance. Their roles include:
- Ensuring stability in blood
- Enabling controlled intracellular release
- Preserving antibody function
- Optimizing therapeutic index
- Allowing or preventing bystander killing
- Influencing DAR, PK, and safety
Linker technology transcends ADCs, driving innovation across biopharmaceuticals:
- Immune Modulation: STING agonist conjugates use pH-sensitive linkers for localized activation in tumor microenvironments.
- Protein Degradation: PROTACs utilize cleavable linkers to connect E3 ligase binders with target protein ligands, enabling ubiquitination and degradation.
- Diagnostic Imaging: Chelating linkers in radioimmunoconjugates (e.g., Lu-177-DOTA) facilitate precise tumor visualization and therapy.
Frequently Asked Questions
Q1: How do we choose between cleavable and non-cleavable linkers?
The decision hinges on target antigen biology. Cleavable linkers suit non-internalizing targets or payloads requiring rapid release, while non-cleavable variants favor internalizing antigens with prolonged payload action. We conduct live-cell assays to model linker behavior in your system.
Q2: Can linkers impact ADC immunogenicity?
Yes. Poorly designed linkers may introduce neoepitopes. Our linkers incorporate humanized sequences and PEGylation to minimize immunogenicity risks.
Q3: What analytical methods validate linker stability?
We employ LC-MS, differential scanning calorimetry, and in vitro plasma stability assays. For advanced projects, microfluidic chips simulate tumor microenvironment conditions.
Reference
- Balamkundu, S.; Liu, C.-F. Lysosomal-cleavable peptide linkers in antibody–drug conjugates. Biomedicines. 2023, 11, 3080.